The Work We Fund

Funded projects
1,250+
Men's Health Partners
20
Countries
20
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Effects of heart glycosides and similar substances on prostate cancer cells

Movember Funding to Date

EUR 73,000

What we seek to achieve

To research and define the in vitro benefit of heart glycosides and similar substances combined with standard prostate cancer pharmaceuticals such as cytotoxic drugs in the advanced stages of prostate cancer.

Country
Germany
Implemented by
Foerderverein Hilfe beim Prostatakrebs e.V. of Organisation
Project start date
January 2015
Project Status
In Progress

About the project

In this study, substances which are already used in cardiovascular diseases will be examined for its effects on the treatment of prostate cancer.
The objective is to combine these substances with existing chemotherapy approaches. Analysis will be performed to determine whether these cardiovascular treatments increase the efficacy of the chemotherapeutic agents and reduce the side effects of these therapies.

Recently marketed new drugs against the advanced stage prostate cancer have not improved survival rates of metastazised prostate cancer patients. Heart glycosides can reduce prostate cancer cell growth without side effects on surrounding normal tissue.
This project will test the effects of heartglycosides on:
1. Prostate cancer proliferation and apoptosis
2. Docetaxel therapy effectiveness and dosis reduction
3. Genes and proteins modifications
4. Potential for improved treatment of  advanced stage prostate cancer patients 

Expertise included in this project: 
Prof. Dr. H. Taubert, university clinic Erlangen:  coordination, statistical evaluation, publication of results
Dr. Sven Wach, labratory, university clinic Erlangen: statistical evaluation, publication of results       
Prof. Dr. W. Kreis, Dr. F. Müller-Uri, institute for pharmaceutical biology Erlangen: provision and validation of heartglycosides 
Prof. Dr. Jörg Rahnenführer , university Dortmund: extended bioinformatic/statistical evaluation

>
Page 1 of 23